Alternative/complementary approaches to treatment of children with autistic spectrum disorders

Infants and Young Children

Volumn 14, Issue 3, 2002, Pages 33-42

  Levy, Susan E ^a,b   Hyman, Susan L ^c,d  

^a CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c Strong Center for Developmental Disabilities   (United States)

^d UNIVERSITY OF ROCHESTER   (United States)

Author keywords

Autism; Autistic spectrum disorders; Complementary and alternative medicine treatments

Indexed keywords

ANTIBIOTIC AGENT; ANTIFUNGAL AGENT; BETHANECHOL; DIPHTHERIA PERTUSSIS TETANUS VACCINE; FAMOTIDINE; FLUCONAZOLE; HEPATITIS VACCINE; IMMUNOGLOBULIN; MAGNESIUM; MEASLES MUMPS RUBELLA VACCINE; MERCURY; NYSTATIN; PYRIDOXINE; SECRETIN; THIOMERSAL; VANCOMYCIN;

ALTERNATIVE MEDICINE; AUTISM; BEHAVIOR DISORDER; CHELATION; CHILD BEHAVIOR; CHILD DEVELOPMENT; COMMUNICATION DISORDER; DETOXIFICATION; DIET; EDUCATION; HUMAN; IMMUNIZATION; RESEARCH; REVIEW; SOCIAL DISABILITY; SOCIALIZATION; TECHNIQUE; THEORY; VITAMIN SUPPLEMENTATION;

EID: 0036020358     PISSN: 08963746     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001163-200201000-00009     Document Type: Review

References (64)

1. Fombonne E. Is there an epidemic of autism? Pediatrics. 2001;107:411-412.
2. Department of Developmental Services. Changes in Population of Persons with Autism and Pervasive Developmental Disorders in California's Developmental Services System: 1987 Through 1998. Report to the Legislature, March 1, 1999. http://www.dds.ca.gov. Accessed October 25, 2001.
3. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th Ed. Washington, DC: American Psychiatric Association; 2000.
4. Lord C, Risi S, Lambrecht L, et al. The autism diagnostic observation schedule-generic: A standard measure of social and communication deficits associated with the spectrum of autism. J Autism Dev Disord. 2000;30:205-223.
5. Stone WL, Lee EB, Ashford L, et al. Can autism be diagnosed accurately in children under 3 years? J Child Psychol Psychiatry. 1999;40:219-226.
6. McEachin JJ, Smith T, Lovaas OI. Long-term outcome for children with autism who received early intensive behavioral treatment. Am J Ment Retard. 1993;97:359-372.
7. Rogers SJ. Empirically supported comprehensive treatments for young children with autism. J Clin Child Psychol. 1998;27:168-179.
8. Volkmar F, Cook EH, Pomeroy J, et al. Practice parameters for the assessment and treatment of children, adolescents, and adults with autism and other pervasive developmental disorders. J Am Acad Child Adolesc Psychiatry. 1999;38(suppl):32S-54S.
9. New York State Department of Health, Early Intervention Program. Autism/Pervasive Developmental Disorders: Assessment and Intervention for Young Children (Age 0-3 Years). Albany, NY: New York State Department of Health; 1999. Publication 4217.
10. Hurth J, Shaw E, Izeman SG, et al. Areas of agreement about effective practices among programs serving young children with autism spectrum disorders. Inf Young Child. 1999;12:17-26.
11. Smith T, Groen AD, Wynn JW. Randomized trial of intensive early intervention for children with pervasive developmental disorder. Am J Ment Retard. 2000;105:269-285.
12. Greenspan SI, Wieder S. Developmental patterns and outcomes in infants and children with disorder of relating and communicating: A chart review of 200 cases of children with autistic spectrum diagnosis. J Dev Learning Disord. 1997;1:87-141.
13. Mesibov GB. A comprehensive program for serving people with autism and their families: The TEACCH model. In: Matson JL, ed. Autism in Children and Adults: Etiology, Assessment, and Intervention. Belmont, CA: Brooks/Cole; 1994.
14. Gordon CT. Psychopharmacological treatments for symptoms and behaviors in autism spectrum disorders. Advocate. November-December 2000:28-31.
15. McDougle CJ, Price LH, Volkmar FR. Recent advances in the pharmacotherapy of autism and related conditions. Child Adolesc Psychiatr Clin North Am. 1994;3:71-89.
16. American Academy of Pediatrics, Committee on Children with Disabilities. The pediatrician's role in the diagnosis and management of autistic spectrum disorder in children (RE060018). Pediatrics. 2001;107(5):1221-1226.
17. Garalnick MJ. The Effectiveness of Early Intervention. Baltimore, MD: Paul H. Brookes; 1997:307-326.
18. Hyman SL, Levy SE. Autistic spectrum disorders: When traditional medicine is not enough. Contemp Pediatr. 2000;17:101-116.
19. Nickel RE. Controversial therapies for young children with developmental disabilities. Inf Young Child. 1996;8:29-40.
20. American Academy of Pediatrics, Committee on Children with Disabilities. Counseling families who choose complementary and alternative medicine for their child with chronic illness or disability (RE 0049). Pediatrics. 2001;107(3):598-601.
21. Sandler AD, Bodfish JW. Placebo effects in autism: Lessons from secretin. J Dev Behav Pediatr. 2000;21:347-350.
22. Bristol MM, Cohen DJ, Costello EJ, et al. State of the science in autism - Report to the National Institutes of Health. J Autism Dev Disord. 1996;26:121-154.
23. 6 and magnesium in the treatment of autism: A methodology review and summary of outcomes. J Autism Dev Disord. 1995;25:481-493.
24. Findling RL, Maxwell K, Scotese-Wojtila L, et al. High-dose pyridoxine and magnesium administration in children with autistic disorder: An absence of salutatory effects in a double-blind, placebo-controlled study. J Autism Dev Disord. 1997;27(4):467-478.
25. Dolske M, Spollen J, Mckay S, et al. A preliminary trial of ascorbic acid as supplemental therapy for autism. Prog Neuropsychopharmacol Biol Psychiatry. 1993;17:765-774.
26. Kern JK, Miller VS, Cauller PL, et al. Effectiveness of N,N-dimethylglycine in autism and pervasive developmental disorder. J Child Neurol. 2001;16(3):169-173.
27. Halsey NA, Hyman SL, Bauman ML, et al. Measles-mumps-rubella vaccine and autistic spectrum disorder: Report from the new challenges in childhood immunizations conference. Pediatrics. 2001. http://www.pediatrics.org/cgi/content/full/107/5/e84. Accessed October 25, 2001.
28. Horvath K, Stefanotos G, Sokolski KN, et al. Improved social and language skills after secretin administration in patients with autistic spectrum disorders. J Assoc Acad Minority Physicians. 1998;9(1):9-15.
29. Owley T, Steele E, Corsello C, et al. A Double Blind, Placebo-controlled Trial of Secretin for the Treatment of Autistic Disorder. MedGenMed. http://www.medscape.com/Medscape/GeneralMedicine/journal/1999/v01.n10/ mgm1006.owle/mgm100. Accessed October 25, 2001.
30. Sandler AD, Sutton KA, DeWeese J, et al. Lack of benefit of a single dose of synthetic human secretin in the treatment of autism and pervasive developmental disorder. N Engl J Med. 1999;341:1801-1806.
31. Chez MG, Buchanan CP, Bagan BT. Secretin and autism: A two-part clinical investigation. J Autism Dev Disord. 2000;30(2):87-94.
32. Dunn-Geier J, Ho HH, Auersperg E. Effect of secretin on children with autism: A randomized controlled trial. DMCN. 2000;42:796-802.
33. Levy SE, Souders MC, Wray J, et al. Comparison of placebo and single dose of human synthetic secretin in children with autistic spectrum disorders. Pediatr Res. 2001;49(4 suppl):427A.
34. Hearings Before the Government Reform Committee, Cong, Sess (April 20, 2000) (testimony of Dr Mary Megson, Richmond, VA).
35. Linday LA. Oral famotidine: A potential treatment for children with autism. Med Hypothesis. 1997;48:381-386.
36. Gupta S, Aggarwal S, Head C. Dysregulated immune system in children with autism: Beneficial effects of intravenous immune globulin on autistic characteristics. J Autism Dev Disord. 1996;11:439-452.
37. Zimmerman AW. Commentary: Immunological treatments for autism: In search of reasons for promising approaches. J Autism Dev Disord. 2000;30:481-484.
38. DelGiudice-Asch G, Simon L, Schmeidler J, et al. Brief report: A pilot open clinical trial of intravenous immunoglobulin in childhood autism. J Autism Dev Disord. 1999;29:157.
39. Pliopys AV. Intravenous immunoglobulin treatment of children with autism. J Child Neurol. 1998;13:79-82.
40. Hornig M, Briese T, Lipkin WI. Bornavirus tropism and targeted pathogenesis: Virus host interactions in a neurodevelopmental model. In: Buchmeier MJ, Campbell IL, eds. Viruses and the Brain. New York: Academic Press; 2001.
41. Singh VK. Plasma increase of interleukin-12 and interferon-gamma: Pathological significance in autism. J Neuroimmunology. 1996;66:143-145.
42. Shaw W, Kassen E, Chaves E. Increased urinary excretion of analogs of Krebs cycle metabolites and arabinose in two brothers with autistic features. Clin Chem. 1995;41:1094-1104.
43. Horvath K, Papadimitriou JC, Rabsztyn A, et al. Gastrointestinal abnormalities in children with autistic disorder. J Pediatr. 1999;135(5):559-563.
44. Crook W. The Yeast Connection. Jackson, TN: Professional Books; 1986.
45. Shattock P, Kennedy A, Rowell F, Berney T. Role of neuropeptides in autism and their relationships with classical neurotransmitters. Part 1. Brain Dysfunction. 1990;3:328-345.
46. Shattock P, Kennedy A, Rowell F, Berney T. Role of neuropeptides in autism and their relationships with classical neurotransmitters. Part 2. Brain Dysfunction. 1991;4:323-334.
47. Pavone L, Fiumara A, Bottaro G, et al. Autism and celiac disease: Failure to validate the hypothesis that a link might exist. Biol Psychiatry. 1997;42:72-75.
48. Reichelt KL, Knivsberg A, Lind G, Modland M. Probable etiology and possible treatment of childhood autism. Brain Dysfunction. 1991;4:308-319.
49. Bird BL, Russo DC, Cataldo MF. Considerations in the analysis and treatment of dietary effects on behavior: A case study. J Autism Child Schizophr. 1977;7:373-381.
50. O'Banion D, Armstrong B, Cummings RA, et al. Disruptive behavior: A dietary approach. J Autism Child Schizophr. 1978;8:325-337.
51. Clark JH, Rhgoden DK, Turner DS. Symptomatic vitamin A and D deficiencies in an eight-year-old with autism. J Parenter Enteral Nutr. 1993;17:284-286.
52. Carvalho NF, Kenney RD, Carrington PH, et al. Severe nutritional deficiencies in toddlers resulting from health food milk alternatives. Pediatrics. 2001;107:E46.
53. Liu T, Howard RM, Mancini AJ, et al. Kwashiorkor in the United States: Fad diets, perceived and true milk allergy, nutritional ignorance. Arch Dermatol. 2001;137:630-636.
54. Kidd PM. Attention deficit/hyperactivity disorder (ADHD) in children: Rationale for its integrative management. Altern Med Rev. 2000;5:402-428.
55. Arnold GA, Hyman SL, Mooney RA. Plasma Amino Acids Profiles in Children with Autism. In press.
56. Rogan WJ, Dietrich KN, Ware JH, et al. The effect of chelation therapy with succimer on neuropsychological development in children exposed to lead. N Engl J Med. 2001;344(19):1470-1471.
57. O'Connor ME, Rich D. Children with moderately elevated lead levels: Is chelation with DMSA helpful? Clin Pediatr. 1999;38(6):325-331.
58. Myers GJ, Davidson PW. Prenatal methylmercury exposure and children: Neurologic, developmental, and behavioral research. Environ Health Perspect. 1998;106:841-847.
59. Grandjean P, Weihe P, White RF, et al. Cognitive deficit in 7-year-old children with prenatal exposure to methylmercury. Neurotoxicol Teratol. 1997;19:417-428.
60. Stratton K, Gable A, Shetty P, McCormick M, eds. Immunization Safety Review: Measles-Mumps-Rubella Vaccine and Autism. Washington, DC: National Academy Press; 2001.
61. Ball LK, Ball R, Pratt RD. An assessment of thimerosal use in childhood vaccines. Pediatrics. 2001;107:1147-1154.
62. Wakefield AJ, Murch SH, Anthony A, et al. Ileal-lymphoid-nodular hyperplasia, non-specific colitis, and pervasive developmental disorder in children. Lancet. 1998;351:637-641.
63. American Academy of Pediatrics. Position paper: Auditory integration training and facilitated communication for autism (RE9752). Pediatrics. 1998;102:431-433.
64. Shaffer RJ, Tuchman RF, Jacokes LE, et al. Interactive metronome: Effect on motor control, concentration, control of aggression, and learning in children with attention-deficit/hyperactivity disorder. Presented at the Interdisciplinary Council on Developmental and Learning Disorders, Third Annual International Conference on Autism and Disorders of Relating and Communicating; November 1999; McLean, VA.